<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600687</url>
  </required_header>
  <id_info>
    <org_study_id>Gilead Study #CO-US-380-4657</org_study_id>
    <nct_id>NCT04600687</nct_id>
  </id_info>
  <brief_title>B/F/TAF Ease of Swallowability Trial</brief_title>
  <acronym>BEST</acronym>
  <official_title>Comparison of the Ease of Swallowability of B/F/TAF Placebo Compared to DTG/ABC/3TC Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will assess the tolerability and swallowability of a STR placebo of B/F/TAF as&#xD;
      compared to DTG/ABC/3TC placebo STR in healthy individuals and HIV antiretroviral naïve&#xD;
      patients. The study team will evaluate the ease of swallow and patient's tolerance of the&#xD;
      medication formulation, an important, yet often overlooked aspect of ART adherence, with the&#xD;
      potential for significant impact on patient's outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will plan to recruit 50 volunteers who will be randomized to receive Placebo A&#xD;
      (B/F/TAF) or Placebo B (DTG/ABC/3TC). Randomization will ensure that the patients will have&#xD;
      equal opportunity to try either placebo tablet first to avoid bias. Randomization will be&#xD;
      done by an investigator not evaluating or providing the questionnaires to the patient.&#xD;
      Participants will complete a questionnaire regarding what medications they take and what&#xD;
      factors they consider affect their ease to swallow pills or tablets. The participants will be&#xD;
      administered one of the placebo tablet with the research investigator present and will&#xD;
      complete a questionnaire immediately following the first placebo dose. A study timeout for&#xD;
      15-30 minutes will be done following completion of the questionnaires. After which,&#xD;
      participants will take the second placebo tablet and complete the final questionnaires.&#xD;
&#xD;
      The primary comparison will be between the placebo tablets A and B for tolerability, ease of&#xD;
      swallow and participant preference. The investigators estimate that the sample size needed to&#xD;
      detect a difference of at least 1 point in a 5 point Likert scale will be 50 patients with a&#xD;
      standard deviation of 2 points, with &gt;90% power.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Actual">October 10, 2020</completion_date>
  <primary_completion_date type="Actual">May 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to take the first placebo tablet and within 30 minutes then take the second placebo tablet. The participants will complete questionnaires prior to taking any placebo pill and after each dose.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Neither the participant nor the person administering the questionnaires will know which placebo tablet the patient has been randomized to receiving first prior to study enrollment. The allocation of which placebo tablet is first swallowed will be randomized in a block randomization design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the ease of swallowability and tolerability of two antiretroviral placebo tablets</measure>
    <time_frame>One hour</time_frame>
    <description>To evaluate the ease and tolerability of swallowing and tolerability of two antiretroviral placebo tablet representing Bictegravir/Emtricitabine/TAF (B/F/TAF) single tablet as compared to a placebo tablet representing Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) by Likert scale questionnaire assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of pill/tablet size of two antiretroviral placebo tablets on acceptability for patients for adherence.</measure>
    <time_frame>One hour</time_frame>
    <description>To assess whether a smaller pill/tablet size is associated with better acceptance by patients by questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tablet characteristics that matter to patients for ease of swallow and for adherence</measure>
    <time_frame>One hour</time_frame>
    <description>To determine which particular tablet characteristic is more important as indicated by patients that affects their acceptance of a particular tablet or medication by questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's ease of swallow and medication preferences impact on medication adherence</measure>
    <time_frame>One hour</time_frame>
    <description>To assess patients' view on how pill/tablet size and ease of swallow impacts their medication adherence by questionnaire using a Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>How patient's cultural differences affect acceptability of pill/tablet size</measure>
    <time_frame>One hour</time_frame>
    <description>To determine if there are any cultural or ethnic differences in pill/tablet acceptance or ease of swallow.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be enrolled in a single arm with a cross over design. Each participant will receive both placebo tablets about 30 minutes apart. Questionnaires will be completed prior to and after each placebo tablet is swallowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV seronegative or seropositive treatment naïve adult over 18 years of age, currently&#xD;
             in stable condition, ambulatory and able to swallow tablets or pills.&#xD;
&#xD;
          2. Patients able to provide informed consent and remain in clinic for at least 2 hours.&#xD;
&#xD;
          3. Study participants able to complete the study questionnaires.&#xD;
&#xD;
          4. No known history of allergies to any of the placebo components.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known dysphagia or motility disorders leading to difficulty swallowing&#xD;
             liquids, food or medications.&#xD;
&#xD;
          2. Patients allergic to any component of the placebo tablets.&#xD;
&#xD;
          3. Children under the age of 18 years.&#xD;
&#xD;
          4. Adults unable to provide informed consent.&#xD;
&#xD;
          5. Female patients known to be pregnant.&#xD;
&#xD;
          6. HIV seropositive patients on antiretroviral therapy or with prior history of&#xD;
             antiretroviral therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. McKinnon, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John McKinnon</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bhosle M, Benner JS, Dekoven M, Shelton J. Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations. Patient Prefer Adherence. 2009 Nov 3;3:161-71.</citation>
    <PMID>19936158</PMID>
  </reference>
  <reference>
    <citation>de Argila CM, Ponce J, Márquez E, Plazas MJ, Galván J, Heras J, Porcel J. Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study. Clin Drug Investig. 2007;27(11):765-70.</citation>
    <PMID>17914895</PMID>
  </reference>
  <reference>
    <citation>FDA. Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules Guidance for Industry June 2015</citation>
  </reference>
  <reference>
    <citation>Fields J, Go JT, Schulze KS. Pill Properties that Cause Dysphagia and Treatment Failure. Curr Ther Res Clin Exp. 2015 Aug 20;77:79-82. doi: 10.1016/j.curtheres.2015.08.002. eCollection 2015 Dec.</citation>
    <PMID>26543509</PMID>
  </reference>
  <reference>
    <citation>Kakuda TN, Berckmans C, De Smedt G, Leemans R, Leopold L, Peeters M, Nijs S, Vyncke V, van Solingen-Ristea R, Hoetelmans RM. Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies. Int J Clin Pharmacol Ther. 2013 Sep;51(9):725-37. doi: 10.5414/CP201770.</citation>
    <PMID>23924679</PMID>
  </reference>
  <reference>
    <citation>Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin Ther. 2005 Jan;27(1):58-63. Erratum in: Clin Ther. 2005 Mar;27(3):360.</citation>
    <PMID>15763606</PMID>
  </reference>
  <reference>
    <citation>Schiele JT, Quinzler R, Klimm HD, Pruszydlo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013 Apr;69(4):937-48. doi: 10.1007/s00228-012-1417-0. Epub 2012 Sep 29.</citation>
    <PMID>23052416</PMID>
  </reference>
  <reference>
    <citation>Singh JA. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther. 2014 Mar 29;16(2):R82. doi: 10.1186/ar4524.</citation>
    <PMID>24678765</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 18, 2020</last_update_submitted>
  <last_update_submitted_qc>October 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>John E. McKinnon, MD, MSc</investigator_full_name>
    <investigator_title>Senior Staff</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>adherence</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After completion of the study and publication of the manuscript(s), the data will be made available for other researchers upon written request and review of the principal investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

